GLP-1 receptor agonists (GLP-1RAs or GLP1s) like semaglutide have been proven to reduce body weight and lessen cardiovascular (CV) risk in patients with type 2 diabetes, butuntil SELECT was publishedthey had not been shown to improve cardiovascular outcomes in patients with a high BMI (aka the obese and overweight**) without diabetes
Brietzke E, Kapczinski F, Grassi-Oliveira R, Grande I, Vieta E, McIntyre RS
B., Pasquato, L
Theres plenty of ways to stay active in Newcastle, from local gyms and fitness classes to parks and recreational facilities
Insert the Ozempic needle into your skin at the chosen injection site (abdomen, thigh, or upper arm)
INDIA DRUG LANDSCAPE On March 21, 2026, Novo Nordisk's patent expired in India